Emergências e Terapia Intensiva
Revisão | Tratamento da hiperglicemia em pacientes internados.
27 Jul, 2021 | 10:10hManaging hyperglycaemia in inpatients – Clinical Medicine Journal
[Preprint] RCT: Em pacientes com COVID-19 e hipóxia grave, a dexametasona 12 mg NÃO resultou em melhora estatisticamente significativa nos desfechos em comparação com a dexametasona 6 mg – “A mortalidade em 28 dias foi de 27,1% e 32,3% em pacientes atribuídos a 12 mg e 6 mg, respectivamente (risco relativo ajustado 0,86, 99% IC, 0,68-1,08).”
26 Jul, 2021 | 10:24hEstudo de coorte mostrou que 1 em cada 2 pacientes hospitalizados com COVID-19 desenvolve complicação.
26 Jul, 2021 | 10:23hComentários:
In-hospital complications associated with COVID-19 – The Lancet
CV Complications Common in Hospitalized COVID-19 Patients – TCTMD
Almost Half of Patients Admitted With COVID-19 Have Complications – HealthDay
Comentário no Twitter (fio – clique para saber mais)
NEW—An observational study of >70,000 people in the UK hospitalised with severe #COVID19 finds 1 in 2 developed at least one health complication. Authors warn of significant challenges for individuals and health & social care in the coming years.
🔗 https://t.co/CTLsPJcGZ7 pic.twitter.com/voMEDVXO9U
— The Lancet (@TheLancet) July 15, 2021
Estudo mostra que o teste de antígeno de fluxo lateral pode detectar, de modo rápido e acurado, a COVID-19 inicial em pacientes com sintomas gripais e pode ser uma alternativa plausível ao RT-PCR.
26 Jul, 2021 | 10:19hComunicado de imprensa: Lateral flow tests are 95% effective at detecting Covid-19 when used at the onset of symptoms – University of Oxford
Relacionado:
Rapid point-of-care tests for diagnosing COVID-19 infection: the latest Cochrane evidence
Comentário no Twitter (fio – clique para saber mais)
Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)
Thread on today's @EDGEclinical paper, with some recommendations at the end for how we can improve UK testing. 🧵
— The Sharing Scientist (@ScienceShared) July 14, 2021
Relato de caso | Síndrome inflamatória multissistêmica similar a doença de Kawasaki associada a infecção por SARS-CoV-2 em adulto.
26 Jul, 2021 | 10:16hRelacionado:
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection
Case Reports: 2 Adults with Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19
Posicionamento Científico | Medicina de precisão na síndrome da angústia respiratória aguda.
26 Jul, 2021 | 10:11hRelacionado:
Review: Personalized mechanical ventilation in acute respiratory distress syndrome.
Seminar | Acute respiratory distress syndrome.
ARDS: Contemporary management and novel approaches during COVID-19
Revisão | Momento e conclusão da revascularização em síndromes coronárias agudas.
26 Jul, 2021 | 10:02hTiming and completeness of revascularisation in acute coronary syndromes – Heart
Comentário no Twitter
Education: Timing and completeness of revascularisation in acute coronary syndromes https://t.co/VBQ76c3545 pic.twitter.com/tpNaZfhrxI
— Heart_BMJ (@Heart_BMJ) July 22, 2021
Editorial | Uso excessivo de antibióticos: gerenciamento da incerteza e mitigação contra o tratamento em excesso.
26 Jul, 2021 | 09:58hAntibiotic overuse: managing uncertainty and mitigating against overtreatment – BMJ Quality & Safety
Comentário no Twitter
Our editorial in @BMJ_Qual_Saf discusses uncertainty and antibiotic overuse, and identifies 4 strategies to address the tendency to prescribe 'just in case'. @EM_Krockow https://t.co/kvIG5uxxOL pic.twitter.com/eTIuqGOj1o
— Prof Carolyn Tarrant (@carolynctarrant) July 21, 2021
Opinião | Tocilizumabe no tratamento da COVID-19: quem se beneficia e como? – Os pesquisadores sugerem que inibidores de IL-6 talvez devam ser ministrados somente a pacientes com altos níveis de IL-6.
23 Jul, 2021 | 10:18hTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Relacionado: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. E M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. E RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes E Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. E M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.